Credit: Getty Images Neurology Advisor explored the controversial approval process of aducanumab for Alzheimer disease and the effects it had on public trust in the US Food and Drug Administration.
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
It’s approved by the Food and Drug Administration (FDA ... the medication and those who were less likely to develop cognitive ...
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...
With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in ...